

## **RCRA Corrective Action**

Cleanup + Productive Use

## **Economic Profile**

# Novartis Pharmaceuticals

Hanover, New Jersey

#### **CONTINUED USE**



Pharmaceuticals Research and Manufacturing

### CLEANUP OVERSEEN

EPA and the New Jersey Department of **Environmental Protection** 

The Novartis Pharmaceuticals facility has been used to develop and manufacture pharmaceutical products since the mid-1950s. Investigations in the mid-1990s found that groundwater at the facility was contaminated with chloroform and several metals. With oversight by EPA and the New Jersey Department of Environmental Protection, all underground storage tanks that were causing the contamination have been removed. Additional investigation is underway to address the site's groundwater contamination and to keep underground vapors from entering buildings.

Throughout the environmental investigation and cleanup process, the facility continues to be an economic engine, providing 4,000 jobs and \$1.8 billion in sales per year.







4,000

\$1.8 billion \$802 million

For more information about RCRA and the economic benefits of site reuse, visit www.epa.gov/hw/learn-about-corrective-action



Novartis recently completed a campus expansion on the revitalized section on the site. This expansion includes collaborative spaces which assist in the development of new cancer treatments. The expansion, completed in 2015, added 1.2 million square feet, bringing the facility's total area to 2.6 million square feet over the 180-acre site. This redevelopment project was recognized with a Merit of Design Award from the American Institute of Architects. Due to the environmentally responsible and sustainable design, the buildings achieved certification by the U.S. Green Building Council.

In order to control energy costs and reduce greenhouse gas emissions, Novartis has committed to reducing its worldwide emissions by 5%. To help meet this goal, Novartis installed a steam-driven back pressure turbine at this facility. The turbine uses high-pressure steam to generate electricity for the plant. The steam is also used as an important part of the company's pharmaceutical research process. Since its installation in 2005, the turbine has generated 1.5 million kilowatt-hours of electricity, saving an estimated \$195,000 in energy costs. Additionally, Novartis installed a 424-module solar array at the site on top of an ENERGY STAR-certified roof. The solar array generates 150,000 kilowatt-hours of electricity each year, a savings of nearly \$30,000. The cleanup and sustainable investments at the property will help protect health both locally and around the world.



The new solar array on top of an ENERGY STAR-certified roof produces 150,000 kilowatt-hours of electricity each year.



Landscaping on the recently expanded part of the site collects and captures stormwater runoff, provides habitat for plants and animals, and recharges the water table.

WITH CLEANUP UNDERWAY, THE NOVARTIS FACILITY CONTINUES TO DRIVE \$1.8 BILLION IN SALES PER YEAR WHILE ALSO IMPROVING ITS SUSTAINABILITY WITH A NEW SOLAR ARRAY AND STEAM-DRIVEN ELECTRICITY.